InteliSwab Covid-19 rapid tests can detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants. Credit: OraSure Technologies.

OraSure Technologies has announced that its InteliSwab Covid-19 rapid tests can detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants.

The Omicron sub-lineage studies, carried out at an independent third-party laboratory, have shown that the test identified the Omicron variants at similar viral load levels as previous variants.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

OraSure Diagnostics president Lisa Nibauer said: “The Covid-19 pandemic remains highly dynamic with new variants of the disease emerging frequently. OraSure is committed to ensuring our science remains robust as we continue to see rapid evolution of the virus over time.

“InteliSwab has performed remarkably well against all new variants of the Covid-19 virus to date, and we will continue to work to ensure that consumers can rely on the accuracy of our test.”

The InteliSwab Covid-19 rapid test is designed to offer results in 30 minutes.

The kit includes a test stick to collect a swab from the lower nostrils. Subsequently, the individual can swirl the test stick in a pre-measured solution to get results.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). It has also received authorisation for Over-the-Counter (OTC) use without a prescription.

Additionally, the FDA has approved the use of InteliSwab Covid-19 Rapid Test Pro for professional use in point of care (POC) clinical laboratory improvement amendments (CLIA)-waived settings as well as the InteliSwab Covid-19 Rapid Test Rx for Prescription Home Use.

Earlier this year, InteliSwab Covid-19 Rapid Tests were approved by the FDA for use in children aged two to 14 years.